Verastem to present updated VS-7375 lung cancer trial data at NACLC 2026
VSTM•
VSTM•Verastem will present updated Phase 1/2 TARGET-D 101 results for VS-7375 at the IASLC/ASCO lung cancer conference on December 5, 2026. Findings reported in October showed confirmed responses in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer.
Verastem will present updated Phase 1/2 TARGET-D 101 results for its investigational oral drug VS-7375 at the IASLC/ASCO lung cancer conference on December 5, 2026. Findings reported in October showed confirmed responses in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer, including patients previously given taxanes; the company said the findings support plans to move the drug toward first-line treatment.
A poster on the Phase 2 TARGET-D 202 registration-directed lung cancer trial will also be presented on December 5. No therapy specifically targeting KRAS G12D is approved.